Healthcare Industry News: oncolytic virus
News Release - December 7, 2006
ImmunoCellular Therapeutics Announces Dr. Robert Martuza, Chief of Neurosurgery at Mass. General, Joins BoardLOS ANGELES--(HSMN NewsFeed)--ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC ; "ICT") is pleased to announce today that Robert Martuza, M.D., has become a member of the Company's Board of Directors.
Dr. Martuza is Chief of Neurosurgery and director of the Stephen E. and Catherine Pappas Center for Neuro-Oncology at Massachusetts General Hospital and Higgins Professor of Neurosurgery at Harvard Medical School. He was recently elected to the prestigious Institute of Medicine ("IOM"), a part of the National Academy of Sciences. The IOM serves in an advisory role on issues of national importance in the fields of biomedical sciences, medicine and health, and provides information to policymakers, professionals, leaders in society and the general public.
Dr. Martuza is a renowned leader in the field of cancer research. His early work focused on the possibility that viruses could be genetically engineered to selectively replicate in cancer cells. This launched the study of oncolytic viruses, which are now studied in laboratories and cancer clinics around the world. Dr. Martuza's work with genetically engineered viruses also has been incorporated into clinical trials for malignant brain tumor therapies. Currently, his clinical interests focus on surgery for nervous system tumors - particularly acoustic neuromas, meningiomas, gliomas and the neurofibromatoses.
"We are delighted to welcome Dr. Martuza on board," said Dr. John Yu, Director and Chief Scientific Officer of ICT. "He is without peer as a researcher, writer, physician and thinker in the field of cancer research. We look forward to working with Dr. Martuza as we develop our exciting new therapies."
In addition to his duties at Massachusetts General Hospital and Harvard Medical School, Dr. Martuza serves as a Director of the American Board of Neurological Surgery. Dr. Martuza is a recognized authority on neurosurgery, has published numerous articles and books in the field of neurology and has 11 patents issued or pending involving virus and cell therapy. Dr. Martuza has received many grants for research with major research interests in central nervous system tumors, neurofibromatosis, cancer therapy with viral vectors and molecular neurosurgery. Dr. Martuza holds a B.A. degree from Bucknell University, Lewisburg, Pennsylvania and an M.D. from Harvard Medical School, Boston, Massachusetts. Dr. Martuza was a post-doctoral fellow at Massachusetts General Hospital.
About ImmunoCellular Therapeutics
ICT is a Los Angeles, California based development stage company that will seek to develop cellular therapies for the treatment of brain and other cancers as well as neurodegenerative disorders. ICT's initial focus will be on a dendritic cell-based vaccine for treating brain tumors, with a Phase I trial for its leading vaccine product candidate targeted for the first quarter of 2007.
This press release contains certain "forward-looking statements" (statements as to matters other than historical facts) as defined in the Private Securities Litigation Reform Act and in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events, projections or results described in the forward-looking statements. These risks and uncertainties include without limitation the need to obtain and possible delays in receiving clearance to commence the Phase I trial and other future clinical trials from the FDA and any medical center involved in the trial; the need to recruit suitable patients for the Phase I trial and other future clinical trials; the risk of losing the services of senior management personnel; the uncertainty of outcomes for the Phase I trial and other future clinical trials; the need to secure appropriate clinical supplies for the product candidate for the Phase I trial and other future clinical trials; and the need to raise significant additional capital to conduct pre-clinical work and clinical trials for product candidates. Additional risks and uncertainties are described in ICT's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K. ICT undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: ImmunoCellular Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.